期刊文献+

儿童先天性心脏病合并重度肺动脉高压根治术随访分析 被引量:8

Follow-up analysis of congenital heart disease complicated with severe pulmonary arterial hypertension in children
下载PDF
导出
摘要 目的:通过对儿童非限制性左向右分流型先天性心脏病合并重度肺动脉高压根治术后的随访,分析超手术指征患儿术后的生存现状并探讨手术指征。方法:收集2005年1月至2016年6月,在我院进行手术治疗的左向右分流型先天性心脏病合并重度肺动脉高压的儿童患者临床资料,所有患儿均有经心导管检查获得的血流动力学资料,随访其术后症状、体征、超声心动图。按术前肺血管阻力指数(PVRI)<6WU/m^2和PVRI≥6WU/m^2分为两组,根据患儿生活质量情况进行生存分析并做Logrank检验,再根据术后是否存在肺动脉高压绘制ROC曲线。结果:59例患儿(男性27例,女性32例),平均8.4岁,主要诊断为室间隔缺损、动脉导管未闭、房间隔缺损、完全型心内膜垫缺损、主肺动脉窗、高压型右室双出口等左向右分流型先天性心脏病,随访时间4~127个月平均69.3个月。PVRI<6WU/m^2组12例(男性6例,女性6例),失访3例,所有患儿随访均无术后PAH;PVRI≥6WU/m^2组患儿47例(男性21例,女性26例),失访15例,除4例患儿随访超声心动图显示无肺动脉高压外,均有不同程度术后肺动脉高压。比较两组患儿无阳性事件的生存曲线,PVRI<6WU/m^2组明显优于PVRI≥6WU/m^2组(Log-rank检验P=0.0496),ROC曲线显示PVRI是预判手术后是否存在肺动脉高压的敏感指标(曲线下面积0.90),且PVRI以8.15WU/m^2为界点时,敏感度为84.2%,特异度为80%。结论:PVRI是评价手术远期预后的关键指标;PVRI<6WU/m^2的患儿手术预后明显好于PVRI≥6WU/m^2的患儿。 Abjective:To analyze the survival status of children out of indication and to discuss the indication through follow-up on children with severe pulmonary hypertension associated with unrestrictive left-right shunt congenital heart disease.Methods:Hemodynamic data and other information are collected from the Children with severe pulmonary arterial hypertension associated with congenital heart disease and treated in Anzhen hospital from January 2005 to June 2016.The survival analysis and log-rank test are executed as well as ROC curve.Results:The object of observation is 59 children (aged 8.4 ± 5.2 years),27 males and 32 females included,with major cardiac malformations of unrestrictive left-right shunt CHD,and follow-up time of 4-127 months mean (69.3 &#177; 33.5)months.12 children belong to Group PVRI 〈 6WU/m2 (6 male and 6 female),3is lost to follow up,and none patient with postoperative PAH.Comparatively,47 patients belong to Group PVRI ≥6WU/m2 (21 male and 26 female),15 lost to follow up,and most of whom still suffered pulmonary arterial hypertension (one of them died 10 months after surgery) except 4 patients.According to postoperative living quality,the prognosis of Group PVRI 〈 6WU/m2 was significantly better than group PVRI ≥ 6WU/m2 (Log-rank test P =0.0496) with the rate of no positive event 86.6% in 3-year,79.2% in 5-year and 22.5% in 10-year.Moreover,PAH may get worse if surgeries are operated on the children out of indication.ROC curve demonstrates that PVRI is a sensitive indicator to predict post-operative pulmonary arterial hypertension(AUC 0.90),with the sensitivity of 84.2%,the specificity of 80.0%,as the boundary point of PVRI 8.15 WU/m2.Conclusion:PVRI is a sensitive indicator for evaluating the long-term prognosis of CHD-PAH surgery.L ong-term surgical outcomes is better in Group PVRI 〈 6WU/m2 than in Group PVRI≥6WU/m2.
作者 程梦佩 张陈 李强强 张丹 赵万桂 刘倩 刘迎龙 顾虹 CHEN Mengpei ZHANG Chen LI Qiangqiang ZHANG Dan ZHAO Wangui LIU Qian LIU Yinglong GU Hong(Department of Pediatric Cardiology, Beijing Anzhen Hospital, Capital Medical University, Belting Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, China)
出处 《心肺血管病杂志》 2017年第7期548-552,共5页 Journal of Cardiovascular and Pulmonary Diseases
关键词 先天性心脏病 肺动脉高压 心脏外科手术 预后 儿童 Congenital heart disease Pulmonary arterial hypertension Cardiac surgery Prognosis Children
  • 相关文献

参考文献4

二级参考文献39

  • 1Singh TP,Rohit M,Grover A,菅鑫妍.口服西地那非疗法治疗严重肺动脉高压的效果研究[J].中国处方药,2006(8):29-29. 被引量:49
  • 2Ewert R,Opitz C,Wensel R,et al.Iloprost as inhalational andintravenous long-term treatment of patients with primary pulmona-ry hypertension.Z Kardiol,2000,89:987-999.
  • 3Berman R,Barst RJ.Pulmonary arterial hypertension:a compre-hensive review of pharmacological treatment.Treat Respir Med,2006,5:117-127.
  • 4Khalil F,Fabrizio S,Roberta S,et al.Treatment of pulmonaryhypertension in patients undergoing cardiac surgery with cardiop-ulmonary bypass:a randomized,prospective,double-blindstudy.Cardiovasc Med,2006,7:119-123.
  • 5Alisa L,Suthep W,Anant K,et al.Aerosolized iloprost of post-operative pulmonary hypertensive crisis in children with congeni-tal heart disease.Int J Cardiol,2008,129:33-338.
  • 6Winterhalter M,Simon A,Fischer S,et al.Comparison of in-haled iloprost and nitric oxide in patients with pulmonary hyper-tension during weaning from cardiopulmonary bypass in cardiacsurgery:a prospective randomized trial.J Cardiothorac VascAnesth,2008,22:406-413.
  • 7Hoeper MM,Schwarze M,Ehlerding S,et al.Long-term treat-ment of primary pulmonary hypertension with aerosolized iloprost,a prostacyclin analogue.N Engl J med,2000,342:1866-1870.
  • 8Olschewski H,Simonneau G,Galie N,et al.Inhaled iloprost forsevere pulmonary hypertension.N Engl J Med,2002,347:322-329.
  • 9Ivy DD,Doran AK,Smith KJ.Short and long-term effects of in-haled therapy in children with pulmonary arterial hypertension.JAm Coll Cardiol,2008,51:161-169.
  • 10Sitbon O,Humbert M,Nunes H.Long-term intravenous epopros-tenol infusion in primary pulmonary hypertension:prognostic fac-tors and survival.J Am Coll Cardiol,2002,40:780-788.

共引文献23

同被引文献94

引证文献8

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部